Renal cell carcinoma: Molecular biology and targeted therapy

Current Opinion in Oncology

Volumn 26, Issue 3, 2014, Pages 321-327

  Su, Daniel ^a   Stamatakis, Lambros ^a   Singer, Eric A ^b   Srinivasan, Ramaprasad ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

immunotherapy; renal cell carcinoma; targeted therapy

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BMS 936559; DOVITINIB; ERLOTINIB; EVEROLIMUS; FIBROBLAST GROWTH FACTOR RECEPTOR 1; IMMUNOMODULATING AGENT; IPILIMUMAB; MAMMALIAN TARGET OF RAPAMYCIN; NIVOLUMAB; PAZOPANIB; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TIVOZANIB; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SPECIFIC SURVIVAL; CANCER SURVIVAL; CHROMATIN; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; IMMUNOMODULATION; KIDNEY CARCINOMA; MOLECULAR BIOLOGY; MOLECULARLY TARGETED THERAPY; MULTICENTER STUDY (TOPIC); ONCOLOGIST; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIGNAL TRANSDUCTION; SYSTEMIC THERAPY; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; HUMANS; IMMUNOTHERAPY; KIDNEY NEOPLASMS; MOLECULAR BIOLOGY; MOLECULAR TARGETED THERAPY;

EID: 84899480870     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0000000000000069     Document Type: Review

References (52)

1. Singer EA, Gupta GN, Srinivasan R. Update on targeted therapies for clear cell renal cell carcinoma. Curr Opin Oncol 2011; 23:283-289.
2. Singer EA, Bratslavsky G, Linehan WM, et al. Targeted therapies for nonclear renal cell carcinoma. Target Oncol 2010; 5:119-129.
3. Siegel R, Ma J, Zou Z, et al. Cancer Statistics, 2014. Ca Cancer J Clin 2014; 64:9-29.
4. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356:115-124.
5. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356:2271-2281.
6. Escudier B, Bellmunt J, Negrier S, et al. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol 2010; 28:2144-2150.
7. Rini BI, Halabi S, Rosenberg JE, et al. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol 2010; 28:2137-2143.
8. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renalcell carcinoma. N Engl J Med 2007; 356:125-134.
9. Motzer RJ, Escudier B, Oudard S, et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 2010; 116:4256-4265.
10. Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010; 28:1061-1068.
11. Rini BI, Escudier B, Tomczak P, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 2011; 378:1931-1939.
12. Singer EA, Gupta GN, Marchalik D, et al. Evolving therapeutic targets in renal cell carcinoma. Curr Opin Oncol 2013; 25:273-280.
13. Coppin C, Le L, Porzsolt F, Wilt T. Targeted therapy for advanced renal cell carcinoma. Cochrane Database Sys Rev 2008; CD006017.
14. Albiges L, Oudard S, Negrier S, et al. Complete remission with tyrosine kinase inhibitors in renal cell carcinoma. J Clin Oncol 2012; 30:482-487.
15. McDermott DF, Regan MM, Clark JI, et al. Randomized phase III trial of highdose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 2005; 23:133-141.
16. Rosenberg SA, Lotze MT, Yang JC, et al. Prospective randomized trial of highdose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J Natl Cancer Inst 1993; 85:622-632.
17. Linehan WM, Srinivasan R, Schmidt LS. The genetic basis of kidney cancer: a metabolic disease. Nat Rev Urol 2010; 7:277-285.
18. Aman A. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 2013; 499:43-49.
19. Johnson DG, Dent SY. Chromatin: receiver and quarterback for cellular signals. Cell 2013; 152:685-689.
20. Dalgliesh GL, Furge K, Greenman C, et al. Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature 2010; 463:360-363.
21. Guo G, Gui Y, Gao S, et al. Frequent mutations of genes encoding ubiquitinmediated proteolysis pathway components in clear cell renal cell carcinoma. Nat Genet 2012; 44:17-19.
22. Varela I, Tarpey P, Raine K, et al. Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature 2011; 469:539-542.
23. Hakimi AA, Chen YB, Wren J, et al. Clinical and pathologic impact of select chromatin-modulating tumor suppressors in clear cell renal cell carcinoma. Eur Urol 2013; 63:848-854.
24. Kapur P, Peñ a-Llopis S, Christie A, et al. Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation. Lancet Oncol 2013; 14:159-167.
25. Motzer RJ, Hutson TE, Cella D, et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med 2013; 369:722-731.
26. Escudier B, Porta C, Bono P, et al. Patient preference between pazopanib (Paz) and sunitinib (Sun): results of a randomized double-blind, placebocontrolled, cross-over study in patients with metastatic renal cell carcinoma (mRCC)-PISCES study, NCT 01064310. J Clin Oncol 2012; 30 (suppl; abstr CRA4502).
27. Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008; 372:449-456.
28. Motzer R, Barrios C, Kim T, et al. Record-3: phase II randomized trial comparing sequential first-line everolimus (EVE) and second-line sunitinib (SUN) versus first-line SUN and second-line EVE in patients with metastatic renal cell carcinoma (mRCC). J Clin Oncol 2013; 31 (suppl; abstr 4504).
29. Patel PH, Senico PL, Curiel RE, et al. Phase I study combining treatment with temsirolimus and sunitinib malate in patients with advanced renal cell carcinoma. Clin Genitourin Cancer 2009; 7:24-27.
30. Feldman DR, Baum MS, Ginsberg MS, et al. Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol 2009; 27:1432-1439.
31. Rini BI, Bellmunt J, Clancy J, et al. Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial. J Clin Oncol 2013; 31: [Epub ahead of print] doi:10.1200/JCO.2013.50.5305.
32. Ravaud A, Barrios C, Alekseev B, et al. Randomized phase II study of first-line everolimus plus bevacizumab (E\+B) versus interferon a-2a plus bevacizumab (I\+B) in patients (pts) with metastatic renal cell carcinoma (mRCC): record-2 final overall survival (OS) and safety results. J Clin Oncol 2013; 31 (suppl; abstr 4576).
33. Nosov DA, Esteves B, Lipatov ON, et al. Antitumor activity and safety of tivozanib (AV-951) in a phase II randomized discontinuation trial in patients with renal cell carcinoma. J Clin Oncol 2012; 30:1678-1685.
34. Motzer RJ, Nosov D, Eisen T, et al. Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial. J Clin Oncol 2013; 31:3791-3799.
35. Welti JC, Gourlaouen M, Powles T, et al. Fibroblast growth factor 2 regulates endothelial cell sensitivity to sunitinib. Oncogene 2011; 30:1183-1193.
36. Korc M, Friesel RE. The role of fibroblast growth factors in tumor growth. Curr Cancer Drug Targets 2009; 9:639-651.
37. Motzer R. Phase 3 trial of dovitinib vs. sorafenib in patients with metastatic renal cell carcinoma after 1 prior VEGF pathway-targeted and 1 prior mTOR inhibitor therapy. European Cancer Congress (ECCO-ESMO-ESTRO); 27 Sept-01 Oct 2013; Amsterdam, the Netherlands.
38. Eisen T, Shparyk Y, Jones R, et al. Phase II efficacy and safety study of nintedanib versus sunitinib in previously untreated renal cell carcinoma (RCC) patients. J Clin Oncol 2013; 31 (suppl; abstr 4506).
39. Yang J, Hughes M, Kammula U, et al. Ipilimumab (anti-CTLA-4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother 2007; 30:825-830.
40. Thompson RH, Dong H, Lohse CM, et al. PD-1 is expressed by tumorinfiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma. Clin Cancer Res 2007; 13:1757-1761.
41. Sznol M, Chen L. Antagonist antibodies to PD-2 and B7-H1 (PD-L1) in the treatment of advanced human cancer. Clin Cancer Res 2013; 19:1021-1034.
42. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366: 2443-2454.
43. Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012; 366:2455-2465.
44. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356:2271-2281.
45. Kroeger N, Xie W, Lee J-L, et al. Metastatic non-clear cell renal cell carcinoma treated with targeted therapy agents: characterization of survival outcome and application of the International mRCC Database Consortium criteria. Cancer 2013; 119:2999-3006.
46. Cecchi F, Rabe DC, Bottaro DP. Targeting the HGF/Met signaling pathway in cancer therapy. Expert Opin Ther Targets 2012; 16:553-572.
47. Kobayashi A, Kang M-I, Okawa H, et al. Oxidative stress sensor Keap1 functions as an adaptor for Cul3-based E3 ligase to regulate proteasomal degradation of Nrf2. Mol Cell Biol 2004; 24:7130-7139.
48. Kinch L, Grishin NV, Brugarolas J. Succination of Keap1 and activation of Nrf2-dependent antioxidant pathways in FH-deficient papillary renal cell carcinoma type 2. Cancer Cell 2011; 20:418-420.
49. Ooi A, Dykema K, Ansari A, et al. CUL3 and NRF2 mutations confer an NRF2 activation phenotype in a sporadic form of papillary renal cell carcinoma. Cancer Res 2013; 73:2044-2051.
50. Stamatakis L, Singer EA, Siddiqui MM, et al. Phase II trial of bevacizumab and erlotinib in patients with advanced hereditary leiomyomatosis and renal cell cancer (HLRCC) or sporadic papillary renal cell carcinoma. Amsterdam, the Netherlands: European Cancer Congress (ECCO-ESMO-ESTRO); 2013.
51. Escudier B, Bracarda S, Maroto J. Open-label phase II trial of first-line everolimus monotherapy in patients with papillary metastatic renal cell carcinoma: RAPTOR final analysis. Amsterdam, the Netherlands: European Cancer Congress (ECCO-ESMO-ESTRO); 2013.
52. Koh Y, Lim HY, Ahn JH, et al. Phase II trial of everolimus for the treatment of nonclear-cell renal cell carcinoma. Ann Oncol 2013; 24:1026-1031.